128 related articles for article (PubMed ID: 36239065)
1. Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence.
Weng X; Zhong L; Xiang P; Li Y; Paciorek A; Dong L; Broering J; Carroll PR; Sanda M; Wilson L
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13740. PubMed ID: 36239065
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of treatment strategies for high risk prostate cancer.
Kowalchuk RO; Kim H; Harmsen WS; Jeans EB; Morris LK; Mullikin TC; Miller RC; Wong WW; Vargas CE; Trifiletti DM; Phillips RM; Choo CR; Davis BJ; Beriwal S; Tendulkar RD; Stish BJ; Breen WG; Waddle MR
Cancer; 2022 Nov; 128(21):3815-3823. PubMed ID: 36070558
[TBL] [Abstract][Full Text] [Related]
3. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
[TBL] [Abstract][Full Text] [Related]
4. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
[TBL] [Abstract][Full Text] [Related]
5. Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis.
Cooperberg MR; Ramakrishna NR; Duff SB; Hughes KE; Sadownik S; Smith JA; Tewari AK
BJU Int; 2013 Mar; 111(3):437-50. PubMed ID: 23279038
[TBL] [Abstract][Full Text] [Related]
6. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
Zubek VB; Konski A
Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiation Therapy.
Levy JF; Khairnar R; Louie AV; Showalter TN; Mullins CD; Mishra MV
Pract Radiat Oncol; 2019 Mar; 9(2):e172-e179. PubMed ID: 30342180
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.
Helou J; Torres S; Musunuru HB; Raphael J; Cheung P; Vesprini D; Chung HT; D'Alimonte L; Krahn M; Morton G; Loblaw A
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):718-731. PubMed ID: 28916284
[TBL] [Abstract][Full Text] [Related]
10. Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer.
Sen S; Wang SY; Soulos PR; Frick KD; Long JB; Roberts KB; Yu JB; Evans SB; Chagpar AB; Gross CP
J Natl Cancer Inst; 2014 Mar; 106(3):dju008. PubMed ID: 24598714
[TBL] [Abstract][Full Text] [Related]
11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Robotic-Assisted Radical Prostatectomy for Localized Prostate Cancer in the UK.
Labban M; Dasgupta P; Song C; Becker R; Li Y; Kreaden US; Trinh QD
JAMA Netw Open; 2022 Apr; 5(4):e225740. PubMed ID: 35377424
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluation of treatments for patients with localized prostate cancer in Europe: a systematic review.
Becerra V; Ávila M; Jimenez J; Cortes-Sanabria L; Pardo Y; Garin O; Pont A; Alonso J; Cots F; Ferrer M;
BMC Health Serv Res; 2016 Oct; 16(1):541. PubMed ID: 27716267
[TBL] [Abstract][Full Text] [Related]
14. A prospective quality-of-life study in men with clinically localized prostate carcinoma treated with radical prostatectomy, external beam radiotherapy, or interstitial brachytherapy.
Lee WR; Hall MC; McQuellon RP; Case LD; McCullough DL
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):614-23. PubMed ID: 11597800
[TBL] [Abstract][Full Text] [Related]
15. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer.
White C; Nimeh T; Gazelle GS; Weinstein MC; Loughlin KR
Cancer; 2019 Mar; 125(6):952-962. PubMed ID: 30561761
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
Amin NP; Sher DJ; Konski AA
Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451
[TBL] [Abstract][Full Text] [Related]
17. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.
Stahl JM; Damast S; Bledsoe TJ; An Y; Verma V; Yu JB; Young MR; Lester-Coll NH
Brachytherapy; 2018; 17(2):399-406. PubMed ID: 29275078
[TBL] [Abstract][Full Text] [Related]
19. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Active Surveillance, Radical Prostatectomy and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
Sharma V; Wymer KM; Borah BJ; Barocas DA; Thompson RH; Karnes RJ; Boorjian SA
J Urol; 2019 Nov; 202(5):964-972. PubMed ID: 31112105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
